🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 21, 2026

Across 50 filings from the S&P 500 Consumer Discretionary stream, dominant themes include heavy institutional portfolio concentration in tech giants (AAPL, MSFT, NVDA across 25+ 13F-HRs totaling billions), mixed Q1 2026 financial performance in consumer-adjacent lenders with average NIM expansion of +25 bps YoY in 5 reporters (Hanmi +25bps QoQ, Northfield +38bps YoY) offset by NAV declines in BDCs (Onex -10% QoQ), and robust capital returns averaging $100M+ programs (Synchrony $6.5B buyback, Donnelley $150M). M&A activity persists with litigation risks (Farmer Bros 14 demands on Royal Cup merger) and SPAC dilutions (AEI CapForce NTBV $7.85 vs $10 IPO), while forward guidance holds steady amid macro pressures (Equifax FY revenue +10-12%). Portfolio-level trends show deposit growth in banks (+1.8% QoQ Hanmi, +8.4% ann. Northfield) but loan declines (-0.3% Hanmi, -5.1% ann. Northfield), signaling cautious lending. Consumer-facing signals mixed: Synchrony purchase volumes +6% YoY but charge-offs monitored monthly; furniture/retail exec departures (Bassett, Simply Good Foods). Implications favor dividend/buyback plays over growth, with catalysts in Q2 mergers/proxy votes.

8 high priority 42 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 21, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (with heavy financial services crossover), Q1 2026 results for reporting companies show average revenue growth of ~8% YoY (range 2-23%, e.g., UNH +2%, ISRG +23%, Danaher +3.7%, MSCI +14%), mixed margins (expansions in UHC +40bps, NIM Hanmi 3.38%; compressions Optum +140bps cost ratio), and resilient earnings (avg +10% YoY). Healthcare standouts include ISRG's 17% procedure growth and Danaher's 11.5% biotech surge, offsetting UNH Optum softness; biotech catalysts like Inhibrx's 20% ORR emerge positively. Capital allocation skews bullish with 8+ buyback/div announcements (Synchrony $6.5B no expiry, UNH $2B Q2, Danaher no Q1 buys vs $1.1B prior). 20+ 13F filings reveal institutional tilt to ETFs (avg 60%+ allocation) and mega-caps (Apple/Microsoft/NVDA ubiquitous), signaling defensive positioning. Guidance mostly raised (UNH FY EPS >$18.25, Danaher $8.35-8.55), but Prudential's sales suspension extension flags Japan risks. Portfolio trend: Regional banks outperforming mega (NIM +48bps YoY Bridgewater vs Cap One -39bps QoQ), healthcare devices/biotech > providers.

6 high priority 44 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 21, 2026

Across 50 DEF 14A proxy statements filed around April 21, 2026, for US SEC-listed companies, a dominant theme is preparation for clustered 2026 annual meetings primarily June 1-16, featuring routine director elections (pluarlity or majority votes), say-on-pay advisory votes, auditor ratifications, and equity incentive plan expansions/amendments in 20+ filings signaling potential dilution risks. Where 2025 financial data is enriched, period-over-period trends reveal stark bifurcation: 9 companies reported robust revenue growth (e.g., AppLovin +70% YoY, Ligand +48% royalties YoY, LendingClub +33% originations YoY) driving positive sentiment, while 2 showed deterioration (Mercer net loss expanded to $(498)M YoY, Cherry Hill BVPS returns negative early quarters with dividend cut from $0.15 to $0.10). Capital allocation highlights shareholder returns via buybacks (AppLovin $2.2B, +$3.2B authorization) and dividends (Power Integrations +2.4% increase), with M&A catalysts like Odyssey's AOM merger (close late Q2/early Q3 2026) and BioMarin's acquisitions. No widespread insider trading data, but leadership transitions (e.g., CEOs in Amerant, Power Integrations) signal governance evolution; portfolio-level, biotech/pharma (12/50) and tech/advertising show outperformance vs. finance/REITs with mixed trends. Implications: Bullish for growth outliers pre-AGM rallies, caution on dilution-heavy plans and weak performers amid neutral sentiment in 70% of filings.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 21, 2026

The IPO Pipeline stream shows a cluster of four high-materiality filings on April 21, 2026, dominated by three S-1 registrations (two SPACs and one operating company), signaling a potential resurgence in blank-check and tech IPO activity amid neutral sentiment across all. Hall Chadwick and East West Ave SPACs feature standard $10/unit structures with sponsor/private commitments totaling millions in warrants/units, while Fusemachines discloses stable YoY customer/supplier concentration risks from 2024-2025 periods. Tecnoglass S-4 proxy emphasizes operational risks ahead of its 2026 AGM for Florida reincorporation and JV benefits with Saint-Gobain. No significant period-over-period financial trends emerge due to pre-IPO nature, but redemption scenarios up to 100% in SPACs highlight dilution risks; sponsor purchases indicate management skin-in-the-game. Market implications include near-term IPO pricing catalysts and watch for SPAC de-SPAC timelines within 24 months, positioning investors for early access to fresh capital raises totaling at least $265M.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — April 21, 2026

The 50 filings reveal a surge in M&A and SPAC activity, with 15+ deals including SoundHound AI's $43M acquisition of LivePerson (22% premium, debt-free post-close), Brady Corp's $1.4B Honeywell PSS buy (8x EBITDA, double-digit EPS accretive), and multiple SPAC mergers like Archimedes/Forge Nano ($1.2B equity value) and Titan/Key Mining ($303M), signaling bullish consolidation in AI, tech, mining, and critical minerals amid $500M+ revenue opportunities. Period-over-period trends show mixed financial health: revenue growth in GE Aerospace (+25% YoY to $12.4B), Danaher (+3.7% to $5.95B), and CMB.TECH (+16% to $1.89B), but margin compressions (GE -490bps GAAP profit margin, Danaher comprehensive income -75%), rising expenses (CMB vessel ops +111%), and deteriorations like Black Hawk net income -79% YoY. Insolvency risks persist in Quadrant Televentures and Setubandhan Infrastructure (CIRP ongoing, plans rejected), alongside delisting threats (Quetta Acquisition). Capital allocation favors buybacks (Aurobindo ₹800Cr, 0.93% shares) and repurchases (AppLovin $2.2B), with positive insider alignment via CrowdStrike's 100K PSUs to President. Sector themes highlight SPAC resurgence in quantum/biotech/healthcare and resource pivots (Sow Good graphite). Portfolio implications: overweight M&A catalysts H2 2026, monitor SPAC redemptions/delays, avoid insolvency-exposed names.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 21, 2026

Across 21 Q1 2026 filings, revenue growth was a dominant theme with 16/21 companies reporting YoY increases averaging +16% (led by GE Aerospace +24.7%, Range Resources +50%, Aircastle +18.8%), though profitability was mixed: 12/21 saw net income growth (avg +35% where positive) but 6 experienced declines (avg -45%), driven by higher expenses and one-offs. Margin compression appeared in 8/21 (e.g., GE Aerospace 26.4% vs 28.7%, 3M EPS -40%), offset by operational leverage in defense (Northrop op income +73%) and leasing (Aircastle EBITDA +19.7%). Capital allocation leaned shareholder-friendly with buybacks in 7/21 (total ~$1.5B, e.g., MSCI $414.8M, Pegasystems $167M) and dividend hikes in 5 (e.g., Northrop $2.31 vs $2.06, Range $0.10 vs $0.09), but cash burns persisted in 9/21 amid acquisitions/investments. Sector strength in aerospace/defense (GE, Northrop, RTX, Aircastle) and water/industrials (Zurn +11.4% sales), contrasted by weakness in small-caps (Fly-E -53% rev, Pacific negative sentiment). Implications: Bullish for large-cap industrials/defense on growth/margins; caution on micro-caps with cash depletion; portfolio rotation toward buyback-heavy names like MSCI/Equifax for near-term returns.

21 high priority 21 total filings
· daily

US SEC Trading Suspension Halt Orders — April 21, 2026

Nine Nasdaq-listed small-cap companies disclosed deficiency notices on April 16-20, 2026, primarily for late Form 10-K filings (6/9 cases: Atlantic American, Allied Gaming, Driven Brands, Laser Photonics, Society Pass, Aimei Health), with others citing bid price violation (Expensify), annual meeting delay (Fly-E Group), and low stockholders' equity (ENDRA Life Sciences); no immediate trading suspensions but delisting risks escalate with clustered compliance deadlines in June-October 2026. Sentiment is negative across 8/9 filings (materiality 9/10 for most), reflecting broad micro-cap distress from accounting delays, administrative lapses, and financial weaknesses. Driven Brands provides the only substantive period-over-period data, showing FY2025 SSS growth of 3.5%-3.7% (Driven) and 6.1%-6.2% (Take 5) vs flat Q4, revenue $1,850-$1,860M (stable YoY implied), Adjusted EBITDA $440-$450M (lower due to restatement), and net debt reduction 24% QoQ to $1.6B with net unit growth of 175 FY2025/29 Q1 2026. Laser Photonics stands out as resolved swiftly (10-K filed, matter closed April 21), while others plan filings/compliance by mid-June. Portfolio-level pattern: 67% tied to reporting failures, signaling sector-wide governance/audit issues; investors face heightened volatility from reverse splits, appeals, and potential OTC transfers. Key implication: Short-term shorts on unresolved names, watch for compliance bounces.

9 high priority 9 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 21, 2026

Across 45 filings in the USA Corporate Distress & Bankruptcy stream (33 new), small-cap distress dominates with 12 companies (e.g., Expensify, Atlantic American, Fly-E Group, Allied Gaming, Society Pass, ENDRA Life Sciences, Aimei Health) receiving Nasdaq deficiency notices for late 10-Ks, low bid prices (<$1), low equity (<$2.5M), or missed shareholder meetings, signaling widespread compliance risks and potential delistings by Q3/Q4 2026. Positive offsets include accretive M&A (SoundHound AI acquiring LivePerson at 22% premium for $500M rev opportunity; Brady acquiring Honeywell PSS at 8x EBITDA, double-digit EPS accretive; NHI divestiture deleveraging to 2.3x net debt/EBITDA) and financings ($90M Prelude Therapeutics offering, $15M Surf Air), but debt restructurings (Reborn Coffee forbearance, NKGen $40M consolidated note) highlight liquidity strains. Limited period data shows mixed trends: Driven Brands Q4 SSS flat (0.3-0.5%) vs FY +3.5-3.7%, Take 5 SSS Q4 +1% vs FY +6.2%; NHI loses $39.7M 2025 lease rev from divestiture. No insider selling clusters, but sparse activity (e.g., Howard Hughes director investing $10M warrants); forward guidance flags H2 2026 catalysts like deal closes (SOUN/LPSN, Onto/Rigaku 27% stake). Portfolio implication: Small-cap consolidation via M&A amid delisting pressures, favor deleveraging plays over compliance laggards.

45 high priority 45 total filings
· daily

US Executive Officer Management Changes SEC — April 21, 2026

Across 32 SEC filings on US executive and director changes dated April 21, 2026, the dominant theme is orderly leadership transitions, with 18 planned retirements/non-re-elections (e.g., CAVA, Radian, Xeris, CION, Trulieve, SandRidge) signaling proactive succession amid neutral sentiment, contrasted by 10 positive appointments/promotions (Delek, Abacus, Envoy, MGE Energy) bringing deep industry expertise. Limited period-over-period financials highlight CrowdStrike's exceptional growth (revenue +57% from $3.06B FY2024 to $4.81B FY2026, ARR +52% to $5.25B, 300% stock return in 95th percentile of S&P 500), while others show capital allocation via equity awards (CrowdStrike 100k PSUs targeting $20B ARR by ~2030, PPG $1.5M MSUs, MGE 25k RSUs) and Adobe's $25B buyback through 2030. Negative outliers include CTO termination at Airgain, chairman resignation over strategy at Lipocine (mixed sentiment), board death at Enigma-Bulwark, and key departures at Masco/Voyager/Timken without immediate successors. Portfolio-level patterns reveal strong AGM support (HP 73.6M-share plan approved, PPG/Warrior unanimous), biotech leadership refreshes (Sagimet/Voyager CMO/CFO shifts), and severance enhancements (Virgin Galactic, Cerus, Robert Half amendments), implying management alignment but watch for execution risks. Market implications favor stability in tech/biotech with growth catalysts, caution in industrials/energy on leadership gaps.

32 high priority 32 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 21, 2026

Across 32 filings on USA board room changes from April 21, 2026, overarching themes include 18 neutral departures/retirements (mostly not due to disagreements), 8 positive appointments/promotions of experienced executives, 3 negative events (death, termination, separation), and supportive annual meeting outcomes with equity plan approvals. Period-over-period trends highlight CrowdStrike's exceptional revenue growth (FY2024 $3.06B to FY2026 $4.81B, +57%; ARR $3.44B to $5.25B, +53%) and 300% stock return (95th percentile S&P 500), contrasting with limited financial deterioration elsewhere; capital allocation favors equity incentives (e.g., Adobe's $25B buyback through 2030, PPG MSUs). Critical developments: Experienced hires in refining (Delek), medtech (Envoy), and promotions (Abacus, MGE) signal continuity; insider-aligned awards (CrowdStrike PSUs to 2028) build long-term conviction. Portfolio-level patterns show sector dispersion—energy/industrials stable, biotech high turnover (5/7 neutral/mixed), tech positive incentives—implying opportunities in leadership-stabilized firms amid M&A expansions.

32 high priority 32 total filings
· daily

US Merger & Acquisition SEC Filings — April 21, 2026

The 13 filings reveal a bifurcated US M&A landscape dominated by SPAC activity (9/13 filings), with fresh IPOs from JATT II ($60M healthcare-focused), APEX Tech (over-allotment full exercise adding $3M), and Maywood 2 ($100M) signaling renewed investor appetite amid no prior period comparisons indicating baseline launches, contrasted by distress in aging SPACs like PHP Ventures (extension contributions cut ~80% from $4,771 to $957/month), Pyrophyte (third extension deposits), Charlton Aria, and Quetta (delisting risks). Operating company M&A highlights include NEXGEL's accretive Celularity acquisition tripling pro-forma annual revenue to $35M with immediate profitability boost and three 510(k) filings planned 2026-2028, XMax's $5.45M investment yielding >99.9% stake in SpaceX-holding fund, and CVB Financial's merger with Heritage scaling assets >$20B, loans ~$12B, deposits ~$17B to become a top-10 California bank holding company. No broad insider trading or dividend/buyback trends reported across filings, but capital locked in SPAC trusts (~$100M+ each for new IPOs) underscores dry powder for future deals; sentiment skews positive (7/13) with high materiality deals (avg 7.7/10). Portfolio-level pattern: SPAC extensions/delays average 3-4 months YoY without business combinations, flagging sector fatigue, while banking consolidation offers scale-driven outperformance. Forward catalysts cluster in late April-May 2026, prioritizing M&A execution over SPAC launches.

13 high priority 13 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 21, 2026

Overnight SEC filings reveal heightened SPAC activity with multiple merger announcements and IPOs in tech, mining, quantum computing, and biotech sectors, signaling robust M&A appetite amid critical minerals demand and AI tailwinds. Earnings and operational updates show mixed results: healthcare giant UnitedHealth Group raised FY2026 adjusted EPS guidance to >$18.25 despite Optum dip, Synchrony Financial posted 6% YoY net earnings growth with new $6.5B buyback, while Allbirds reported Q1 net loss of $19.6M on 27.8% gross margins. Period-over-period trends indicate financials resilient (e.g., NIM expansion at First United to 3.83%, charge-offs down 96 bps at Synchrony), but loan stagnation and covenant waivers flag banking stress. 24 of 50 filings are 13F-HR disclosures dominated by tech giants (Apple, NVDA, MSFT) and ETFs, reflecting institutional conviction in growth equities. Capital allocation leans bullish with buybacks/div hikes (Synchrony 13% div increase, UNH $2B repurchase), but shelf registrations (PAVmed, Battalion Oil) highlight dilution risks. Portfolio-level patterns show 70%+ of 13F value in tech/ETFs, positioning for AI/semicon rally; watch Q2 catalysts like annual meetings and SPAC closings for alpha.

15 high priority 35 medium 50 total filings
· daily

Biotech Small-Cap Approvals — April 20, 2026

The FDA approved 8 Other (FALLBACK) category products between April 20 and April 20, 2026, with a mix of 0 NMEs, 0 biosimilars, and 0 label expansions, all generating neutral investment signals of medium strength and materiality. These approvals involve diverse small molecule products across sponsors like TEVA PHARMS INC, AUROBINDO PHARMA LTD, and BAXTER HLTHCARE CORP, including GLYCEROL PHENYLBUTYRATE, METHOTREXATE SODIUM, and DEXMEDETOMIDINE HYDROCHLORIDE. No dominant therapeutic area theme or clustering is evident from the data. The highest-conviction signal is TEVA PHARMS INC's neutral approval for GLYCEROL PHENYLBUTYRATE, implying modest portfolio diversification upside for the sponsor amid NOT_DISCLOSED commercial details. Key risk/watch item: absence of peak sales, exclusivity, and pricing data necessitates monitoring post-launch performance and competitive uptake.

8 total filings
· daily

Big Pharma Approvals — April 20, 2026

This period featured 3 'Other' approvals (0 NMEs, 0 biosimilars, 0 label expansions), all classified as bullish label expansions for big pharma stalwarts GENENTECH INC's INAVOLISIB (ITOVEBI), ASTRAZENECA AB's EPLONTERSEN SODIUM (WAINUA Autoinjector), and JANSSEN BIOTECH's USTEKINUMAB (STELARA). No dominant therapeutic area theme emerges, with approvals spanning diverse indications. Highest-conviction signal is JANSSEN BIOTECH's USTEKINUMAB label expansion, extending STELARA's immunology franchise reach and supporting revenue defensiveness amid patent cliffs. All signals carry moderate strength (5/10) and materiality (5/10), highlighting steady lifecycle management execution. Key risk/watch item: NOT_DISCLOSED commercial details (peak sales, exclusivity, pricing) necessitate monitoring post-approval uptake and competitive encroachment.

3 total filings
· daily

Orphan Drug Approvals — April 20, 2026

During the narrow period of April 20-20, 2026, FDA Orphan Drug approvals featured a mix of 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other approval, yielding 1 bullish signal with no bearish or neutral outcomes. AstraZeneca AB's EPLONTERSEN SODIUM (WAINUA autoinjector) label expansion approval delivers the highest-conviction bullish signal, enhancing delivery options for this orphan drug and signaling potential improvements in patient convenience and uptake. No dominant therapeutic area theme is evident from this single approval. Key risk/watch item is limited visibility into peak sales, exclusivity, pricing, and market position, all marked NOT_DISCLOSED, warranting monitoring of post-approval commercialization.

1 total filings
· daily

New Drug Approvals (Original) — April 20, 2026

The FDA granted 8 Other approvals from April 15-20, 2026, reflecting a mix of 0 NMEs, 0 biosimilars, 0 label expansions, and routine generic-like entries despite summary descriptions labeling them as biosimilars. No dominant therapeutic area theme is evident, as indications are unknown or commodity generics with no clustering. All 8 signals are neutral (strength/materiality 5/10), with no highest-conviction standout; GLYCEROL PHENYLBUTYRATE by TEVA PHARMS INC exemplifies incremental portfolio addition absent commercial catalysts. Key risk/watch item: monitor generic entrants like METHOTREXATE SODIUM (ALEMBIC) and DEXMEDETOMIDINE HYDROCHLORIDE (BAXTER HLTHCARE CORP) for pricing erosion in mature markets, though peak sales and exclusivity remain NOT_DISCLOSED.

8 total filings
· daily

DHS Homeland Security Contracts — April 20, 2026

DHS obligated $598,444,871 across one civilian contract with zero defense-related exposure, centered on ICE detention, transportation, and medical logistics at Camp East Montana in El Paso, TX. ACQUISITION LOGISTICS LLC secured this bullish award via full and open competition after exclusion, signaling strong demand for small disadvantaged business capabilities in border enforcement. The highest-conviction signal is the $598M obligation with potential upside to $1.34B through 2027-09-30, representing ~$299M annualized revenue estimate for the Henrico, VA-based firm. A key risk is high pricing/execution risk under the firm fixed price structure with zero outlays to date and current performance end of 2026-04-17. Investors should differentiate this as pure DHS/ICE civilian growth, distinct from DOD durability.

1 total filings
· daily

VA Healthcare & Services Contracts — April 20, 2026

The VA Healthcare & Services contract stream delivered a single high-materiality award totaling $170,623,805 in obligations, entirely civilian with 0/1 defense-related contracts. Department of Veterans Affairs awarded Booz Allen Hamilton Inc. a firm fixed price delivery order for Benefits Enterprise Services under NAICS 541512, signaling bullish IT support growth for the contractor with base + options value up to $456,716,346. This full and open competition win underscores VA Technology Acquisition Center's focus on enterprise IT in Washington, DC, starting April 17, 2026. Highest-conviction signal is bullish revenue potential for Booz Allen Hamilton Inc. amid positive Tech sector exposure. Key risk is high execution and pricing risk with zero outlays to date and options uncertainty beyond 2027-04-16.

1 total filings
· daily

New Federal Contractors — April 20, 2026

Three new federal contracts totaling $993,948,995 in obligations, all civilian with zero defense-related awards, highlight bullish signals in DHS logistics and IT services for GSA and VA. The highest-conviction signal is Acquisition Logistics LLC's $598,444,871 DHS delivery order for detention, transportation, and medical services at Camp East Montana, representing 60% of the aggregate value and a potential $1.34B with options through 2027. Dominant sector theme is civilian agency commitments to logistics consulting (NAICS 541614) and computer systems design (NAICS 541512). General Dynamics One Source LLC and Booz Allen Hamilton Inc. add $224.9M and $170.6M respectively in stable GSA and VA IT services. Key risk is zero outlays across all contracts (negative -$60K for General Dynamics), signaling execution and funding delays ahead.

3 total filings
· daily

Significant Contract Modifications ($10M+) — April 20, 2026

Three significant civilian contract modifications totaling $993,948,995 in obligations signal bullish growth in non-defense sectors, with 0/3 defense-related awards across DHS, GSA, and VA. The dominant theme is civilian agency commitments to logistics and IT services, led by Acquisition Logistics LLC's highest-materiality $598,444,871 DHS delivery order for detention support. All signals are bullish with average strength 6.3/10, reflecting full-and-open competition wins by diverse firms including small disadvantaged and large incumbents. Highest-conviction signal is Acquisition Logistics LLC's award, with potential upside to $1.34B through 2027. Key risk is execution amid zero outlays on two awards and negative outlays on General Dynamics One Source LLC's GSA contract; watch initial outlay progress and option exercises.

3 total filings